Clinical study on the efficacy and safety of Kunbi Xiao Prescription in the treatment of female rheumatoid arthritis

Xi Yuan Hospital of China Academy of Chinese Medical Sciences0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•? Female RA patients who meet the diagnostic criteria of Western medicine and TCM syndrome of Toxic Heat, Phlegm and Blood Stasis Accumulation Syndrome;
•?Age 18-65 years old;
•? Disease activity score (DAS28) > 3.2 and = 5.1;
•? Those who did not participate in any drug trials within 4 weeks before enrollment;
•? Voluntary subjects and signed informed consent.

•? Women who are pregnant, breastfeeding, and plan to become pregnant during treatment and/or within 12 weeks after treatment;
•? Patients with serious primary diseases or mental illness such as cardiovascular, liver, kidney and hematopoietic system;
•? Patients who have been diagnosed with other connective tissue diseases such as systemic lupus erythematosus, Sj?gren's syndrome, myositis or dermatomyositis;
•? Patients with pituitary tumor, hyperthyroidism, ovarian cyst and other endocrine diseases, or have a history of uterine and ovarian surgery, or have taken oral contraceptives in recent 4 weeks;
•? Those who do not meet the requirements for combined medication;
•? Patients who are known to be allergic to any of the traditional Chinese medicines used in this test, or allergic constitution (allergic to two or more drugs, food, pollen);
•? Patients with a history of substance abuse, drug or alcohol abuse;
•? Other situations that the researcher considers unsuitable to be selected for this project.

发起方

Xi Yuan Hospital of China Academy of Chinese Medical Sciences